Pluri Inc.

Regulatory Filings • Jan 9, 2018

_________ false

�������� ��������� ����	2 380
PLURISTEM THERAPEUTICS INC
Corporation no: C12337-2001	8544
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	09/01/2018
	www.isa.gov.il			www.tase.co.il				Reference:	2018-02-002901	Time of broadcast: 13:55 13:23:11

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	Delay the publication of a report	_________	_________

1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onFDA Clears Pluristem�s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study

Expanded_Access_Program_CLI_final_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 01/01/2018
Address: Matam Park 5 , Haifa 31905   ISRAEL , Tel: 074-7107171 , Fax: 074-7107172
E-mail address: Info@Pluristem.Com   Company site: www.pluristem.com
Previous names of reporting entity:
Name of the Signatory: Aberman Zalman Position of Signatory in the reporting corporation: Chairman Of The Board & CEO Name of Employer Company:
Address: Matam Park 20 , Haifa 31905 Telephone: 074-7107171 Facsimile: 074-7107172 E-mail: zami@pluristem.com 2